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Expression and Targeting of CX3CL1 (Fractalkine) in Renal
Tubular Epithelial Cells
Anne M. Durkan,*† R. Todd Alexander,*† Guang-Ying Liu,† Min Rui,† Giuseppe Femia,†
and Lisa A. Robinson*†
*Division of Nephrology and †Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada
The chemokine CX3CL1 plays a key role in glomerulonephritis and can act as both chemoattractant and adhesion molecule.
CX3CL1 also is upregulated in tubulointerstitial injury, but little is known about the subcellular distribution and function of
CX3CL1 in renal tubular epithelial cells (RTEC). Unexpectedly, it was found that CX3CL1 is expressed predominantly on the
apical surface of tubular epithelium in human renal transplant biopsy specimens with acute rejection or acute tubular
necrosis. For studying the targeting of CX3CL1 in polarized RTEC, MDCK cells that expressed untagged or green fluorescent
protein–tagged CX3CL1 were generated. The chemokine was present on the apical membrane and in subapical vesicles. Apical
targeting of CX3CL1 was not due to signals that were conferred by its intracellular domain, to associations with lipid rafts, or
to O-glycosylation but, rather, depended on N-linked glycosylation of the protein. With the use of fluorescence recovery after
photobleaching, it was found that CX3CL1 is immobile in the apical membrane. However, CX3CL1 partitioned with the
triton-soluble rather than -insoluble cellular fraction, indicating that it is not associated directly with the actin cytoskeleton
or with lipid rafts. Accordingly, disruption of rafts through cholesterol depletion did not render CX3CL1 mobile. For
exploration of potential functions of apical CX3CL1, binding of CX3CR1-expressing leukocytes to polarized RTEC was
examined. Leukocyte adhesion to the luminal surface was enhanced significantly when CX3CL1 was present. These data
demonstrate that CX3CL1 is expressed preferentially on the apical membrane of RTEC and suggest a novel function for the
chemokine in recruitment and retention of leukocytes in tubulointerstitial inflammation.
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R enal tubulointerstitial inflammation is characterized byrecruitment of circulating leukocytes to the site of in-jury. Traffic signals for leukocyte migration are pro-
vided by chemokines, a family of small molecular weight pro-
teins (1). Among the chemokines, CX3CL1 (fractalkine) has a
unique role in the inflammatory cascade because of its struc-
ture: an extracellular chemokine domain and mucin stalk, teth-
ered to a transmembrane region and a 37–amino acid cytoplas-
mic tail. Transmembrane CX3CL1 is cleaved proximal to the
membrane by metalloproteinases of the A disintegrin and met-
alloproteinase (ADAM) family to release a soluble species (2–5).
Soluble CX3CL1 acts as a chemoattractant, whereas the trans-
membrane protein acts as a cell adhesion molecule for mono-
cytes, natural killer (NK) cells, and subsets of CD8 T cells, all
of which express CX3CR1, the receptor for CX3CL1. In this way,
CX3CL1 and CX3CR1 promote leukocyte infiltration at sites of
injury (2,6,7). In vivo, CX3CL1 is strongly implicated in inflam-
mation, including allograft rejection and, most notably, athero-
genesis (8–13).
Numerous organs express CX3CL1, including brain, lung,
heart, intestine, and kidney (10,14–17). In humans and rodents,
CX3CL1 expression is prominent in renal glomerular disease,
particularly in endothelial and mesangial cells (18–20). The role
of CX3CL1 in mediating glomerular injury is well described in
animal models of systemic lupus erythematosus nephritis, me-
sangioproliferative glomerulonephritis, and crescentic glomer-
ulonephritis (21–23). In these disease processes, blockade of
either CX3CL1 or CX3CR1 prevents renal injury and leukocyte
infiltration (21–23). Little is known, however, regarding the role
of CX3CL1 in tubulointerstitial renal disease. Expression of
CX3CL1 clearly is enhanced in tubulointerstitial injury, includ-
ing that associated with tubular protein overload and acute
allograft rejection (19,24,25). However, knowledge regarding
the subcellular distribution and function of CX3CL1 in renal
tubular epithelial cells (RTEC) is rudimentary.
We demonstrate here that CX3CL1 is present on the apical
membrane of RTEC, where it is anchored firmly. We further
demonstrate that CX3CL1 is targeted to the apical membrane
via N-glycosylation of the chemokine. The implications of api-
cal targeting of CX3CL1 for the pathogenesis of tubulointersti-
tial inflammation are discussed.
Materials and Methods
Cells and Constructs
HK-2 cells were a gift from Dr. Andras Kapus, (University of To-
ronto, Toronto, ON, Canada). MDCK cells were from American Type
Culture Collection (Manassas, VA). MDCK cells that stably expressed
sodium-hydrogen exchanger 3 (NHE3) tagged with hemagglutinin
(HA) were provided by Dr. Sergio Grinstein (University of Toronto).
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The preceding cells were cultured in DMEM and Ham’s F12 (Wisent,
St-Bruno, Quebec, Canada) that contained 5% FCS. K562 erythroleuke-
mia cells and K562 cells that stably expressed CX3CR1 (K562-CX3CR1)
were from Dr. Dhavalkumar Patel (University of North Carolina,
Chapel Hill, NC) and were cultured in RPMI supplemented with
HEPES and 15% FCS. Primary human RTEC (Clonetics, Cambrex,
Walkersville, MD) were a gift from Dr. Jim Scholey (University of
Toronto) and were cultured according to the manufacturer’s instruc-
tions (26). CX3CL1 expression in these cells was verified by Western
blotting (27). Human peripheral blood mononuclear cells (PBMC) were
isolated from heparinized peripheral blood from healthy volunteers
(28).
DNA constructs for CX3CL1 or CX3CL1 tagged with green fluores-
cent protein (CX3CL1-GFP) were created as described previously
(6,27,29). MDCK cells were stably transfected with these constructs
using FuGENE (Roche, Indianapolis, IN) and selected in 500 g/ml
G418 (Wisent).
The predicted transmembrane portion of CX3CL1 ends at amino acid
360 (PSORT II). A mutant construct that lacked amino acids 361 to 397,
CX3CL1–360, was generated by PCR using the common upstream
primer 5-GTGGAATTCTGCAGTCGACTC-3 and the downstream
primer 5-GCGGCCGCTCACATGGCCACCCCCAGGCAG-3. In the
downstream primer, stop codons and NotI sites were introduced. PCR
products were cloned into TOPO vector (Invitrogen, Burlington, ON,
Canada) and sequenced. Inserts were released by cutting with NotI and
EcoRI and subcloned into HA-pcDNA3.1 (Invitrogen). MDCK cells
were transfected using FuGENE and selected in 500 g/ml G418
(MDCK-CX3CL1–360). DNA constructs that encoded GFP-tagged gly-
cosyl phosphatidylinositol (GPI-GFP) and FcRIIa receptor (FcR-GFP)
were a gift from Dr. S. Grinstein (University of Toronto) (30,31).
Antibodies and Reagents
The following antibodies were used: Goat anti-human CX3CL1 di-
rected against the extracellular chemokine region (R&D Systems, Min-
neapolis, MN) (19,32), goat anti-human CX3CL1 against the intracellu-
lar carboxy terminus (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-actin (Sressgen, Victoria, BC, Canada), and anti-HA (Covance,
Berkeley, CA). Cy3- and horseradish peroxidase–conjugated anti-goat
IgG, anti-mouse IgG, and 18 nm gold-labeled anti-goat IgG were from
Jackson Immunoresearch Laboratories (Bar Harbor, ME). Tunicamycin,
benzyl-2-acetamido-2-deoxy--d-galacto-pyranoside, and methyl--cy-
clodextrin (MCD) were from Sigma-Aldrich (St. Louis, MO). Amplex
Red kit was used to measure cholesterol levels (Molecular Probes,
Eugene, OR). Cholera toxin B conjugated to Alexa fluor 555 was from
Molecular Probes. The metalloprotease inhibitors TAPI-2 and GM6001
were from Peptides International (Louisville, KY) and Chemicon Inter-
national (Temecula, CA), respectively. TNF- was from R&D Systems.
Immunohistochemistry
Renal transplant biopsy specimens were obtained in accordance with
the guidelines of the Research Ethics Board of University Health Net-
work (University of Toronto). Frozen 7-M sections were air-dried and
fixed in acetone. After blocking with 5% donkey serum, sections were
incubated with anti-CX3CL1 antibody (Ab), followed by Cy3-conju-
gated anti-goat IgG.
Immunofluorescence staining of cultured cells was performed as
described previously (33). For detection of surface CX3CL1, cells were
fixed and labeled with anti-CX3CL1 Ab and Cy3-conjugated secondary
Ab. For detection of surface and intracellular CX3CL1, the same cells
were permeabilized with 0.1% Triton X-100 and incubated again with
anti-CX3CL1 Ab and Cy5-conjugated secondary Ab. In some experi-
ments, Alexa 488–conjugated phalloidin was added with the secondary
Ab to label F-actin. Cells were visualized using either an LSM 510
confocal microscope (Zeiss, Toronto, ON, Canada) or a spinning disk
DMIRE2 confocal microscope (Leica Microsystems, Toronto, ON, Can-
ada), equipped with an Hamamatsu backthinned EM-CCD camera.
Images were acquired using 100 oil immersion and the appropriate
filters. Z stacks were constructed and images deconvolved using Ve-
locity software (Improvision, Lexington, MA).
PCR
RNA was isolated from HK-2 cells using Trizol (Life Technologies,
Burlington, ON, Canada), and reverse transcriptase–PCR for CX3CL1
was performed using oligo(dT) and specific primers (24). PCR products
were size-fractionated on 1% agarose in TBE gels and stained with
ethidium bromide.
Immunoblotting
SDS-PAGE and immunoblotting were performed using anti-CX3CL1
Ab (0.2 g/ml) (27,34). Immunoreactive bands were visualized by
enhanced chemiluminescence (Amersham Biosciences UK Limited,
Buckinghamshire, UK) recorded on x-ray film. Detergent resistance
was assessed as described previously (34). Triton-soluble and -insolu-
ble components were compared with total cell lysate.
Electron Microscopy
Scanning electron microscopy (EM) was performed as described
previously using anti-CX3CL1 Ab (1 g/ml) and 18 nm of gold-labeled
anti-goat IgG secondary antibody (34).
Fluorescence Recovery after Photobleaching
Experiments were performed as described previously (34,35). Briefly,
the apical surface was brought into focus on a confocal microscope, and
two 2.5-m diameter areas of similar fluorescence intensity were se-
lected per cell. After acquisition of baseline measurements, one defined
area was photobleached irreversibly, and fluorescence of both areas
was measured over time. Fractional fluorescence recovery of the
bleached area was determined relative to prebleach measurements. The
unbleached area was used to control for inadvertent bleaching during
repeated image acquisition. Results are expressed as the mean fluores-
cence recovery for at least six experiments, with SEM.
Adhesion Assays
Experiments were performed as described elsewhere with minor
modifications (10). Briefly, MDCK-CX3CL1-GFP cells were grown to
confluence on 25-mm coverslips and pretreated with 10 M TAPI-2 for
2 h to maximize cell surface expression of CX3CL1. K562-CX3CR1 cells
were labeled with cholera toxin B-555, and 1  106 cells were added to
wells of either MDCK or MDCK-CX3CL1-GFP cells with gentle rocking
at 10 cycles/min. Nonadherent cells were washed away, and remaining
cells were fixed and mounted onto slides. Using a Leica deconvolution
microscope, we examined at least 50 high-power fields (63) to count
the number of adhered cells. Results are the mean of three separate
experiments with SEM and were compared using paired t test. Cells
also were examined using a spinning disk confocal microscope.
Results
CX3CL1 Is Expressed in RTEC
To define the functions of CX3CL1 in RTEC, we first exam-
ined CX3CL1 expression in five human renal allograft biopsy
specimens. Three specimens had histologic diagnosis of acute
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rejection and two of acute tubular necrosis. In all five speci-
mens, we detected CX3CL1 expression in renal tubules, partic-
ularly on the apical surface (Figure 1, A and B). In addition to
being expressed on tubular epithelium, modest CX3CL1 expres-
sion was noted within the glomeruli and on vascular endothe-
lium (data not shown). This is in keeping with a previously
published report (19). To verify the specificity of staining, we
omitted primary anti-CX3CL1 Ab from some experiments.
When the secondary Ab alone was used, very little background
immunofluorescence was observed (data not shown). At our
institution, donor preimplantation renal transplant biopsies are
not performed routinely and therefore could not be used as an
additional negative control. However, using the same anti-
CX3CL1 Ab as the one used in our study, other investigators
previously reported minimal immunohistochemical expression
of CX3CL1 in normal renal biopsy tissue (19,32). We then ex-
amined expression and subcellular distribution of CX3CL1 in
HK-2 cells, a human RTEC line. Using reverse transcriptase–
PCR, we detected CX3CL1 mRNA (Figure 1C). To verify
CX3CL1 protein expression, we performed immunofluores-
cence staining and again found the chemokine predominantly
at the apical surface (Figure 1D).
CX3CL1 Is Expressed in the Apical Membrane of RTEC
Because HK-2 cells, unlike other tubular epithelial lines,
grow in flattened monolayers, we adopted another approach,
stably expressing full-length CX3CL1 or CX3CL1-GFP in MDCK
cells, a renal cell line with cuboidal morphology that is typical
of epithelial cells, facilitating distinction between apical and
basolateral surfaces. Using Western analysis and anti-CX3CL1
Ab, MDCK-CX3CL1 and MDCK-CX3CL1-GFP cells each dis-
played a single band of appropriate molecular weight (Figure
2A). For assessment of the subcellular localization of CX3CL1,
MDCK-CX3CL1-GFP cells (Figure 2B) were fixed and incubated
with anti-CX3CL1 Ab, which labeled only the apical surface
(Figure 2C). For visualization of intracellular CX3CL1, the same
cells then were permeabilized and incubated with anti-CX3CL1
Ab followed by a different secondary Ab. This confirmed an
intracellular pool of CX3CL1 in subapical vesicles (Figure 2D).
To confirm that any labeling of MDCK-CX3CL1-GFP cells with
anti-CX3CL1 Ab was specific for CX3CL1, we incubated un-
transfected MDCK cells with the same Ab. In this instance, no
immunofluorescence staining was observed (data not shown).
To control further for any background staining of Cy3- or
Cy5-conjugated secondary Ab used, we also performed exper-
iments in which the primary Ab was omitted. Once again,
incubation with secondary Ab alone yielded no immunofluo-
rescence labeling (data not shown). Collectively, these results
demonstrate that CX3CL1 is expressed on the apical plasma
membrane as well as within subapical vesicles.
In MDCK-CX3CL1-GFP cells, GFP is attached to the cytoplas-
mic tail of the chemokine. Because the tagged construct was
recognized by the Ab directed against the extracellular domain
of CX3CL1, the protein expressed must traverse the apical
membrane (Figure 2, B and E). We also noted a second pool of
GFP, present in the basolateral membrane (Figure 2B). After
permeabilization, the basolateral pool of GFP could be labeled
by an anti-CX3CL1 Ab directed against the intracellular domain
of the chemokine (data not shown). We believe that basolateral
GFP represents the intracellular portion of CX3CL1 that re-
mains after the extracellular segment has been proteolytically
released. Accordingly, Western analysis of MDCK-CX3CL1-
GFP cells using anti-GFP Ab consistently revealed two separate
bands. The molecular masses of these bands correlated with
full-length CX3CL1-GFP fusion protein (Figure 2A) or a fusion
protein corresponding to the intracellular region of CX3CL1
together with GFP (35 kD; data not shown). To ensure that the
GFP tag did not alter subcellular traffic of CX3CL1, we exam-
ined MDCK cells that expressed the untagged chemokine and
found a similar distribution (Figure 2F).
We used scanning EM to confirm that CX3CL1 is expressed
on the apical membrane of RTEC. As shown in Figure 2G,
CX3CL1 is associated with microvilli on the apical surface.
CX3CL1 Is Targeted to the Apical Membrane by
N-Glycosylation
We next investigated the signals that target CX3CL1 to the
apical membrane. Apical sorting of transmembrane proteins
can be determined by signals that are conferred by the cyto-
plasmic tail of the protein (36,37), by O- or N-glycosylation (38),
or by membrane anchoring of the protein through GPI or
directly to lipid rafts (39). We examined each of these potential
mechanisms.
Figure 1. CX3CL1 is expressed in human renal tubular epithelial
cells (RTEC). Immunofluorescent labeling of CX3CL1 in human
renal allograft biopsy specimens, with histologic diagnoses of
acute tubular rejection (A) and acute tubular necrosis (B). Sam-
ples were labeled with anti-CX3CL1 antibody (Ab) and Cy3-
conjugated secondary Ab. (C) Total RNA was isolated from
HK-2 cells, and CX3CL1 was amplified by reverse transcripta-
se–PCR using specific published primers. The PCR products
were size-fractionated on 1% agarose. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) is shown as a control. (D)
Immunofluorescence staining of HK-2 cells using anti-CX3CL1
Ab and a Cy2-conjugated secondary Ab. Actin was labeled
with rhodamine-conjugated phalloidin. Arrows demonstrate
CX3CL1 labeling on the apical surface of cells.
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To determine whether the cytosolic tail of CX3CL1 mediates
apical targeting, we generated a mutant construct that lacked
the cytoplasmic domain (CX3CL1–360). We examined the dis-
tribution of CX3CL1 in MDCK cells that stably expressed “tail-
less” CX3CL1 but found that the protein still was directed to the
apical membrane (Figure 3A).
We next assessed potential associations of CX3CL1 with lipid
rafts. We treated cells with MCD to extract cholesterol,
thereby disrupting lipid rafts (40). To ensure that MCD treat-
ment was effective, we measured cholesterol spectrophoto-
metrically (41). MCD depleted total cellular cholesterol by
58% (P  0.05; Figure 3B) but had no effect on apical targeting
of CX3CL1 (Figure 3C).
We next examined glycosylation of CX3CL1 as a determinant
of apical targeting. O-glycosylation was inhibited with benzyl-
2-acetamido-2-deoxy--d-galacto-pyranoside. Again, CX3CL1
targeting to the apical membrane remained intact (Figure 3D).
To inhibit N-glycosylation of CX3CL1, we treated cells with
tunicamycin. This treatment resulted in intracellular retention
of CX3CL1 with virtually no expression observed on the apical
surface (Figure 3E). To verify that the observed effects were not
due to nonspecific disruption of apical protein traffic, we eval-
uated the effects of tunicamycin on NHE3, a protein that does
not require N-glycosylation for its apical targeting. As ex-
pected, tunicamycin treatment did not affect the normal apical
distribution of NHE3 (Figure 3F).
Collectively, these data indicate that the signals that direct
apical trafficking of CX3CL1 are not conferred by the protein’s
cytoplasmic domain, O-glycosylation of the protein, or associ-
ations with lipid rafts. Rather, apical localization of CX3CL1 is
determined by N-glycosylation.
CX3CL1 Is Anchored to the Apical Membrane in RTEC
To determine whether CX3CL1 is anchored in the luminal
surface, we used fluorescence recovery after photobleaching to
study the mobility characteristics of apical CX3CL1-GFP in
MDCK-CX3CL1-GFP cells (see Materials and Methods) (Figure
4, A [before bleaching], B [immediately after bleaching], and C
[5 min after bleaching]). As a control, MDCK cells were trans-
fected with a DNA construct that encoded GPI-GFP, which is
freely mobile in the apical plasma membrane. A region of the
apical membrane was bleached similarly, and the recovery of
fluorescence was observed over time (Figure 4, D through F).
CX3CL1-GFP recovered with significantly slower kinetics than
GPI-GFP (Figure 4G). For CX3CL1-GFP, the bleached area re-
covered to 10.5 4.3% of prebleached fluorescence intensity by
4 min, compared with 61.1  11.9% for GPI-GFP (P  0.01). As
an additional control, MDCK cells were transfected with DNA
that encoded the single transmembrane protein FcR-GFP.
When fluorescence recovery after photobleaching was per-
formed similarly, the bleached area in the membrane recovered
significantly faster than CX3CL1-GFP, with 4-min recovery of
51.5  6.1% for FcR-GFP (P  0.01; Figure 4G). These data
demonstrate that the ability of CX3CL1 to diffuse laterally
within the apical membrane is impeded, and, therefore, trans-
membrane CX3CL1 is immobile.
Some single-pass transmembrane proteins are tethered to the
apical membrane by direct association with lipid rafts (42). To
determine whether CX3CL1 is anchored in such a manner, we
disrupted lipid rafts by treating cells with MCD. However,
this treatment did not mobilize CX3CL1 in the apical membrane
(Figure 4G). To study whether apical CX3CL1 is immobile
because it is tethered directly to the actin cytoskeleton, we
Figure 2. CX3CL1 is expressed on the apical surface of RTEC.
(A) Western analysis was performed using cell lysates from
control wild-type MDCK cells (WT), MDCK-CX3CL1-GFP, and
MDCK-CX3CL1 cells, using anti-CX3CL1 Ab and horseradish
peroxidase (HRP)-conjugated secondary Ab. For MDCK-
CX3CL1-GFP and MDCK-CX3CL1 cells, bands of predicted mo-
lecular weight were obtained, namely 116 and 90 kD, respec-
tively. (B through E) Immunofluorescence labeling of MDCK-
CX3CL1-GFP cells was performed as in Materials and Methods,
and cells were examined by spinning disk confocal microscopy.
(B) Spinning disk confocal image of MDCK-CX3CL1-GFP cells.
(C) For visualization of CX3CL1 at the cell surface, MDCK-
CX3CL1-GFP cells were fixed before incubation with anti-
CX3CL1 Ab and Cy3-conjugated anti-goat IgG secondary Ab.
(D) For visualization of both surface and intracellular CX3CL1,
cells were fixed and permeabilized before incubation with anti-
CX3CL1 Ab and Cy5-conjugated secondary Ab. (E) Merged
images B through D. Images are shown as x versus y and x
versus z optical sections. (F) Examination of the subcellular
distribution of untagged CX3CL1. For visualization of cell sur-
face CX3CL1, MDCK-CX3CL1 cells were fixed, then incubated
with anti-CX3CL1 Ab, followed by Cy3-conjugated anti-goat
IgG secondary Ab. For visualization of any intracellular
CX3CL1 present, the same cells then were permeabilized and
incubated again with anti-CX3CL1 Ab followed by Cy5-conju-
gated secondary Ab. (G) MDCK-CX3CL1-GFP cells were la-
beled with anti-CX3CL1 Ab and gold-conjugated secondary Ab
and examined using scanning electron microscopy. Arrows
show the association of the CX3CL1 with apical microvilli.
Reverse-phase images are shown. Magnification, 100 in B
through E.
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fractionated cellular proteins between two distinct fractions—
triton soluble and triton insoluble—as described previously
(33). In polarized epithelial cells, proteins that were anchored
directly to the actin cytoskeleton preferentially remain in the
triton-insoluble fraction. We found, however, that CX3CL1
largely was soluble in triton solution, suggesting that it is not
tethered directly to the actin cytoskeleton (Figure 4H). These
data also confirm that CX3CL1 is not associated with lipid rafts
(Figures 3C and 4G). Collectively, these data indicate that after
sorting to the apical surface, CX3CL1 is held immobile there,
but this is not achieved by direct tethering to the actin cytoskel-
eton or by association with lipid rafts.
CX3CL1 Expressed on the Apical Surface of RTEC Promotes
Adhesion of Leukocytes
CX3CL1 can act as a cell adhesion molecule, facilitating the
binding of leukocytes (7,43). We therefore hypothesized that
CX3CL1 might perform a similar function when expressed on
Figure 3. Targeting of CX3CL1 to the apical membrane of RTEC. (A) MDCK cells that expressed a mutant CX3CL1 construct that lacks
the cytoplasmic tail (MDCK-CX3CL1–360) were fixed and then incubated with anti-CX3CL1 Ab and a Cy3-conjugated secondary Ab to
visualize cell surface CX3CL1. For further visualization of intracellular CX3CL1, the same cells thenwere permeabilized and then labeled
with anti-CX3CL1 Ab and then Cy5-conjugated secondary Ab. After permeabilization, cells were incubated with Alexa 488–conjugated
phalloidin to label F-actin. Slides were examined using a spinning disk confocal microscope. Images are shown as x versus y and x versus
z optical sections. (B) For depletion of cholesterol and disruption of lipid rafts, MDCK-CX3CL1-GFP cells were incubated for 30 min at
37°C with methyl--cyclodextrin (MCD), and the cholesterol content was measured by spectrophotometry using Amplex Red
(Molecular Probes). Values for cholesterol content are expressed as a percentage of untreated controls and represent a mean of three
experiments (*P  0.05). (C) MDCK-CX3CL1-GFP cells were incubated for 30 min with MCD before fixation and incubation with
antibodies as in A. (D) MDCK-CX3CL1-GFP cells were labeled with anti-CX3CL1 Ab, as in A, after treatment with benzyl-2-acetamido-
2-deoxy--d-galacto-pyranoside overnight to inhibit O-glycosylation. (E) MDCK-CX3CL1-GFP cells were labeled with anti-CX3CL1 Ab
as in A after overnight treatment with tunicamycin to inhibit N-glycosylation. (F) MDCK cells that expressed HA-tagged NHE3
(MDCK-NHE3) were incubated overnight with tunicamycin. The cells then were fixed and incubated with anti-HA Ab and then
Cy3-conjugated secondary Ab. For visualization of intracellular NHE3, the same cells were permeabilized and then incubated with
anti-HA Ab and then Cy5-conjugated secondary Ab. After permeabilization, the cells also were incubated with Alexa 488–conjugated
phalloidin to label F-actin.
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the apical surface of RTEC. Under the low-shear conditions
used, there was minimal binding of control K562 leukocytes to
either MDCK or MDCK-CX3CL1-GFP cells (data not shown).
We found significant binding of K562-CX3CR1 leukocytes to
MDCK-CX3CL1-GFP cells (Figure 5, A and B). When CX3CL1
was present on the apical membrane, leukocyte adhesion was
almost three times greater than when CX3CL1 was absent (P 
0.001; Figure 5C).
To verify that any observed responses were not an idiosyn-
cratic feature of transformed cell lines, we performed the same
experiments using primary, untransfected cells. Human PBMC
Figure 4. CX3CL1 is anchored to the apical membrane in RTEC. For
examination of the mobility of CX3CL1 in the apical membrane,
fluorescence recovery after photobleaching (FRAP)wasperformedas
described in Materials and Methods. Using an argon laser and a
scanning confocal microscope, a 2.5-M region of the apical mem-
brane that expressed CX3CL1-GFP was photobleached irreversibly
(circles), and recovery of fluorescence was monitored over time. (A)
MDCK-CX3CL1-GFP cell before bleaching. (B) The same cell imme-
diately after photobleaching. (C) The same cell 5 min later. Control
areas of the same diameter in the plasmamembrane were examined
at each time point. (D through F) As a control, FRAPwas performed
similarly in MDCK cells that expressed freely mobile glycosyl phos-
phatidylinositol conjugated to GFP (MDCK-GPI-GFP). (D) MDCK-
GPI-GFP cells before bleaching. (E) The same cell immediately after
bleaching. (F) The same cell after 5 min of recovery. (G) As an
additional control, FRAP was performed in MDCK cells that ex-
pressed the single transmembrane protein FcIIa receptor tagged
with GFP (FcR-GFP). Recovery of fluorescence after photobleaching
of apical CX3CL1-GFP, GPI-GFP, FcR-GFP, and CX3CL1-GFP after
cholesterol depletion was done with MCD. Points represent the
mean  SEM of recovery at serial time points from at least six
experiments. (H) Lysates from MDCK-CX3CL1-GFP cells were ob-
tained after separation into triton-soluble and triton-insoluble frac-
tions, as described in Materials and Methods. Western blotting
was performed using anti-CX3CL1 Ab and HRP-conjugated second-
ary Ab.
Figure 5. CX3CR1-expressing leukocytes adhere to CX3CL1 in
the apical membrane of RTEC. K562 cells that expressed the
CX3CR1 receptor (K562-CX3CR1) were labeled with rhodam-
ine-conjugated cholera toxin B to visualize them. K562-CX3CR1
cells (1  106) were added to MDCK or MDCK-CX3CL1-GFP
monolayers, growing on 25-mm cover slips, under conditions
of low-shear stress. After 20 min, nonadherent cells were re-
moved by washing, and the remaining cells were fixed. Serial
fields (63) were examined, using a Leica deconvolution mi-
croscope, and the number of adherent cells were counted. (A
and B) Photomicrographs of labeled K562-CX3CR1 cells (red)
binding to MDCK-CX3CL1-GFP monolayers. Images shown in
x versus y (A) and x versus z (B) optical sections. (C) Graph
depicting the number of K562-CX3CR1 leukocytes bound to
either MDCK or MDCK-CX3CL1-GFP cells. Values represent
the mean number of adherent cells per high-power field (63).
Values represent the mean of three experiments  SEM (*P 
0.001). (D) Adhesion assays were repeated using primary RTEC
and human peripheral blood mononuclear cells (PBMC) that
were isolated from the blood of healthy volunteers. In parallel
experiments, primary RTEC monolayers were preincubated
with function-blocking anti-CX3CL1 Ab (1 g/ml) for 30 min
before addition of PBMC. Values represent the mean number of
adherent PBMC per40 field. Experiments were performed six
times for each condition (*P  0.0001 versus control).
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were isolated from heparinized blood of healthy volunteers.
PBMC contain multiple leukocyte subsets, including CD8 T
lymphocytes, monocytes, and NK cells, all of which express the
CX3CR1 receptor. PBMC efficiently adhered to the apical sur-
face of monolayers of primary human RTEC. When primary
RTEC were preincubated with function-blocking anti-CX3CL1
Ab, binding of PBMC was inhibited significantly (Figure 5D).
Collectively, these data suggest that CX3CL1 expressed on the
luminal surface of RTEC promotes adhesion of leukocytes that
bear the complementary receptor CX3CR1. Our results are in
keeping with previous reports in which blockade of CX3CL1/
CX3CR1 impaired binding of THP-1 monocytic cells to primary
proximal RTEC (32).
Discussion
The expression and the function of CX3CL1 in endothelial
cells have been well described (6,7,27,43). In the kidney, an
important role for CX3CL1 has been found in diseases that
involve glomerular inflammation and endothelial injury
(19,20,22,23). CX3CL1 also is upregulated in renal tubulointer-
stitial inflammation, most notably in acute allograft rejection
(19), but the specific localization of the chemokine (apical versus
basolateral) has been somewhat unclear (32). The purpose of
these studies, therefore, was to ascertain the subcellular distri-
bution and targeting of CX3CL1 in polarized tubular epithelial
cells. Unexpectedly, we found that transmembrane CX3CL1
was expressed predominantly on the apical surface of RTEC.
This pattern of expression mirrors that found in epithelial cells
of biliary ductules (44) but differs markedly from that of intes-
tinal epithelial cells, where CX3CL1 largely is expressed in the
basolateral membrane and in regions of intercellular contact
(45,46). In the intestine, as in the kidney, expression of CX3CL1
is highly enhanced in disease states that are marked by active
inflammation (14,45,47).
We next examined how CX3CL1 is sorted to the apical mem-
brane. In polarized cells, several signals can sort transmem-
brane proteins to either the basolateral or the apical membrane.
The sorting determinant may lie in the cytoplasmic, transmem-
brane, or extracellular domain of the protein. Sorting signals in
the cytoplasmic tail include PDZ domains and dileucine motifs,
used by the cystic fibrosis transmembrane regulator and the
IgG Fc receptor, respectively (36,37). By deleting the cytoplas-
mic tail of CX3CL1, we excluded an apical targeting signal in
this region. Other transmembrane proteins, such as Thy-1, api-
cally target through direct or indirect associations with lipid
rafts (48). However, when we disrupted any potential associa-
tion with rafts by extracting cholesterol, we found no change in
the distribution of CX3CL1.
Carbohydrate modification of the protein backbone also may
direct trafficking of transmembrane proteins, as is the case for
sucrase isomaltase, which requires O-glycosylation for apical
targeting (38). CX3CL1 has 26 O-glycosylation sites in the mu-
cin stalk. However, when we inhibited O-glycosylation,
CX3CL1 still trafficked to the apical membrane. For other pro-
teins, such as endolyn and the glycine transporter GLYT2,
N-glycosylation is the crucial determinant of apical targeting
(49,50). CX3CL1 has a single N-glycosylation site, located in the
chemokine domain (2). Our studies indicate that glycosylation
of this site is the key signal that directs CX3CL1 to the apical
membrane.
We postulated that after translocating to the apical mem-
brane, CX3CL1 would become anchored there, positioning it to
act as a cellular adhesion molecule (7,10,43,51). Firm anchoring
of the chemokine within the membrane would allow it to tether
passing cells that express the receptor CX3CR1. Our experi-
ments indicate that CX3CL1 indeed is immobile, similar to
another adhesion molecule, CD44 (42,52).
We next considered how CX3CL1 might be physically an-
chored to the apical membrane. Some adhesion molecules,
including CD44, are tethered to the cell membrane by direct
association with lipid rafts. We therefore examined the effect of
cholesterol depletion and disruption of rafts on apical tethering
of CX3CL1. Disruption of lipid rafts did not increase the lateral
mobility of CX3CL1. Moreover, CX3CL1 segregated with the
detergent-soluble, rather than -insoluble, cellular fraction, fur-
ther refuting a direct association with lipid rafts. These data
also suggest that CX3CL1 is not anchored directly to the actin
cytoskeleton. A recent model of membrane fluidity proposed
that transmembrane proteins might be fenced into discrete
regions of the membrane (53). Such a mechanismmight account
for the limited lateral mobility of CX3CL1. Alternatively,
CX3CL1 could be anchored indirectly to the actin cytoskeleton
by one or more triton-soluble adaptor proteins (54).
Although our studies demonstrate that CX3CL1 is targeted
and anchored within the apical membrane, the key question is
what role it might play there. CX3CL1 in intestinal epithelium
has been shown to recruit leukocytes in inflammation and to
regulate cell survival and wound repair (7,45,55). In intestinal
epithelium, CX3CL1 is expressed predominantly on the baso-
lateral surface, where it is in direct contact with CX3CR1-ex-
pressing host leukocytes, including macrophages, lympho-
cytes, and dendritic cells. In the lamina propria, basolateral
CX3CL1 tethers dendritic cells to intestinal epithelium. Adher-
ent dendritic cells then form transepithelial protrusions, which
they extend into the gut lumen, facilitating immunosurveil-
lance and defense against enteroinvasive bacteria (46). In con-
trast, no such immunosurveillance is known to occur within the
kidney or the intrahepatic biliary tree. In biliary ductular epi-
thelial cells, CX3CL1 is expressed both apically and basolater-
ally (44,47). CX3CL1 on the apical surface of regenerating bili-
ary epithelial cells has been implicated in repair of the biliary
tree after acute injury, presumably by recruiting hepatic stem
cells, which express CX3CR1 (47). In RTEC, a similar role has
been proposed for CD44. CD44 normally is expressed on the
basolateral membrane, where it participates in cell–matrix in-
teractions. However, after renal tubulointerstitial injury, CD44
is expressed apically, where it is thought to promote regener-
ation and repair (56,57).
Conclusion
We have found that CX3CL1 on the apical membrane pro-
motes tethering of leukocytes that bear the complementary
receptor. During tubulointerstitial renal inflammation, tight
junctions break down, potentially allowing leukocytes to es-
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cape into the urinary space. We postulate that apical CX3CL1
facilitates recruitment and retention of these leukocytes, redi-
recting them to the site of injury. In this manner, CX3CL1 may
play an important role in tubulointerstitial nephritis, pyelone-
phritis, and renal allograft rejection, disease processes in which
expression of CX3CL1 is highly upregulated. As with biliary
epithelial cells, CX3CL1 also may participate in regeneration of
tubules after inflammatory injury. Further work is needed to
ascertain the in vivo functions of CX3CL1 located on the apical
membrane of RTEC.
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